We examined 134 pediatric clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa, and grampositive cocci for susceptibility to aztreonam alone and in combination with seven other antibiotics. All 
Aztreonam, a monobactam (17) , has excellent activity against aerobic gram-negative bacteria, especially Enterobacteriaceae (4, 16) and Pseudomonas aeruginosa (2, 9) . Because of its lack of activity against gram-positive and anaerobic organisms, it will likely be used with other agents in the initial therapy of serious infections in appropriate pediatric patients, such as newborns and immunocompromised and post-surgical patients. Important pathogens in these patients include group B Streptococcus, Staphylococcus, Listeria, and various gram-negative bacteria, including P. aeruginosa. Therefore, initial antimicrobial combinations with aztreonam are likely to include ampicillin, cefoxitin, nafcillin, and clindamycin, as well as aminoglycosides and other antipseudomonal antibiotics. Hence, the susceptibilities of common pediatric pathogens to aztreonam alone and in appropriate antimicrobial combinations were examined in our laboratory.
MATERIALS AND METHODS
Antibiotics. Aztreonam was supplied as the anhydrous, crystalline, P-form by E. R. Squibb & Sons, Princeton, N.J.
it was dissolved in a saturated solution of sodium bicarbonate, diluted to a stock concentration of 1,280 ,ug/ml with distilled water, and frozen in small samples at -70°C. All stock solutions were used within 4 weeks of preparation. Ampicillin, cefoxitin, clindamycin, nafcillin, tobramycin, piperacillin, and ticarcillin were provided by their respective manufacturers. Stock solutions were prepared in concentrations of 1,000 to 2,000 ,ug/ml, frozen, and used within 4 weeks of preparation.
Bacteria This is comparable to the fractional inhibitory concentration index as described by Elion et al., (1) , in which synergism occurs if the fractional inhibitory concentration is s0.5 and antagonism occurs when the fractional inhibitory concentration is >2. For gram-positive organisms, all of which were resistant to aztreonam, synergy or antagonism was defined as a fourfold change in the MIC of the grampositive antibiotic at a pharmacokinetically attainable concentration of aztreonam (128 to 256 p.g/ml) (15) .
Timed bacterial killing of selected isolates was measured on organisms grown overnight and diluted to a concentration of 10' CFU/ml in Mueller-Hinton broth (18) . Antibiotics, alone and in combination, were added at concentrations equal to the MIC of each drug alone. The mixture was incubated at 37°C on a rotary shaker at 100 rpm for 24 h. Samples were removed, serially diluted, and plated on agar for determination of viable organism counts before the addition of antibiotics and 2, 6, and 24 h after incubation with antibiotics. Synergism was defined as a 100-fold decrease in the number of bacteria killed by the combination as compared with the most effective single antibiotic. Antagonism was present if the number of bacteria increased 10-fold with the combination as compared with either single antibiotic.
RESULTS
Gram-negative isolates were susceptible to aztreonam at therapeutically achievable concentrations (Table 1) . At the inoculum size of approximately 5 x 105 CFU/ml, 27 of 98 isolates showed a difference between MIC and MBC values with the criterion of >99.9% kill. Only five of these (one E. coli, two P. mirabilis, two P. aeruginosa) had as much as a fourfold difference. In comparison, only 12 isolates had MIC-MBC differences under the >99% kill criterion, of which two were fourfold increases. The 36 gram-positive isolates were resistant to aztreonam, although 4 of 12 group B Streptococcus isolates had MICs of 64 jig/ml.
Synergism of aztreonam and cefoxitin against E. coli, Klebsiella spp., Shigella spp., and Salmonella spp. was common ( Table 2) . Combinations of aztreonam with ampicillin were noninteractive. Clindamycin plus aztreonam was frequently synergistic against E. coli and Klebsiella spp. Antagonism was seen only with cefoxitin plus aztreonam against Enterobacter species (three E. cloacae and two E. aerogenes) and against one isolate of S. marcescens. In these instances, cefoxitin increased the aztreonam MIC values four-to eightfold, which made them, therefore, no greater than 2 ,ug/ml.
The synergistic combinations of bacterial strains and antibiotics were randomly distributed within strains. Susceptibility to one antibiotic combination was not predictive of susceptibility to another.
The combinations of aztreonam and tobramycin, aztreonam and ticarcillin, and aztreonam and piperacillin were synergistic against 10 of 16 (62%), 1 of 16 (6%), and 3 of 16 (18%) P. aeruginosa isolates, respectively. No antagonism was seen with any combination. Two of the three strains susceptible to the synergistic activity of piperacillin and aztreonam were also synergistically susceptible to tobramycin and aztreonam. No differences in synergistic activity were seen between mucoid and nonmucoid strains.
Aztreonam did not antagonize the activity of any tested antimicrobial agent against gram-positive cocci. Although aztreonam alone had no appreciable activity against any gram-positive strain, aztreonam plus ampicillin and aztreonam plus cefoxitin were synergistic against one and two isolates of group B Streptococcus, respectively. Aztreonam plus clindamycin was synergistic against 2 of 12 isolates of group D Streptococcus. The activity of nafcillin against 12 isolates of S. aureus was unaffected by the presence of aztreonam.
The bactericidal effects of selected antibiotics were also determined in time-kill experiments. These studies confirmed the results of the checkerboard assays with Pseudomonas. Figure 1 shows the synergistic activity of tobramycin and aztreonam against P. aeruginosa strain 2; this pattern was confirmed with two other P. aeruginosa isolates. With a strain of Enterobacter which had shown antagonism to the combination of cefoxitin and aztreonam in checkerboard experiments, time-kill analysis revealed that the combination was equivalent to the activity of cefoxitin alone (Fig. 2) . Enterobacter strain 17 showed similar killing curves (data not shown). Both of these isolates were also tested at inoculum sizes of 2 x 106 to 3 x 106 CFU/ml, and the killing curves were similar.
Time-kill curves prepared for isolates of E. coli, Klebsiella spp., and Salmonella spp. did not reveal interactions not shown by the checkerboard microdilution studies. with such antagonism. Even so, if the mechanisms postulated are correct, the adverse interaction may be expected to increase with prolonged exposure of the organism to cefoxitin, the inducing agent. Caution is probably indicated, therefore, in using aztreonam plus cefoxitin in Enterobacter or Serratia infections.
DISCUSSION
The dynamics of bacterial killing studied in time-kill experiments confirmed the synergism noted against many isolates of P. aeruginosa and some members of Enterobacteriaceae by the checkerboard method. The interaction seemed most effective during exponential growth. The timed killing studies against Enterobacter did not show the antagonism noted by the checkerboard method. This discrepancy may be related to the inherent differences between measurements of inhibitory and bactericidal activity. The prolonged exposure of bacteria to drugs in the kinetic experiments may have led to better penetration of antimicrobial agent into the bacterial cell, despite the postulated binding of aztreonam to beta-lactamases. Alternatively, the limited number of antibiotic concentrations tested in the time-kill experiments may have missed those most likely to reveal the antagonism (5). The time-kill curve is, however, generally still considered more reflective of in vivo activity (6) .
Our results lend additional support for the potential role of aztreonam in treating pediatric infections. In association with ongoing pharmacokinetic and safety studies, they should provide valuable guidelines for selection of aztreonam regimens in future clinical trials.
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